GLUE Earnings

Quarterly EPS
$-0.29
Q3 2024
$0.16
Q4 2024
$0.57
Q1 2025
$-0.15
Q2 2025
$-0.33
Q3 2025
$-0.54
Q4 2025
$-0.45
Q1 2026
$-0.43
Q2 2026
Latest Revenue9.0M
Latest Net Income-43397000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.439.0M-43397000-61.3%-186.7%
Q1 2026-$0.454.2M-44503000-95.0%-178.9%
Q4 2025-$0.542.8M-46135000-95.4%-437.5%
Q3 2025-$0.3312.8M-27081000+38.5%-13.8%
Q2 2025-$0.1523.2M-12295000+394.0%+65.1%
Q1 2025$0.5784.9M46.9M+7,882.0%+207.5%
Q4 2024$0.1660.6M13.4M+127.6%
Q3 2024-$0.299.2M-23859000+58.6%
Q2 2024-$0.434.7M-30310000
Q1 2024-$0.531.1M-31968000
Q4 2023-$0.580-33252000
Q3 2023-$0.700-34884000
Monte Rosa Therapeutics (GLUE) — Earnings